Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Kinami T, Uchikawa S, Kawaoka T, Yamasaki S, Kosaka M, Johira Y, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Fujino H, Nakahara T, Ono A, Murakami E, Okamoto W, Yamauchi M, Miki D, Tsuge M, Oka S. Kinami T, et al. Among authors: okamoto w. Cancer Med. 2024 Mar;13(5):e7025. doi: 10.1002/cam4.7025. Cancer Med. 2024. PMID: 38477514 Free PMC article.
MET amplification as a potential therapeutic target in gastric cancer.
Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K, Yamada Y. Kawakami H, et al. Among authors: okamoto w, okamoto i. Oncotarget. 2013 Jan;4(1):9-17. doi: 10.18632/oncotarget.718. Oncotarget. 2013. PMID: 23327903 Free PMC article.
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K. Kidera Y, et al. Among authors: okamoto w, okamoto i, okamoto k. Int J Clin Oncol. 2011 Jun;16(3):244-9. doi: 10.1007/s10147-010-0170-6. Epub 2011 Jan 18. Int J Clin Oncol. 2011. PMID: 21243395
Targeting MET Amplification as a New Oncogenic Driver.
Kawakami H, Okamoto I, Okamoto W, Tanizaki J, Nakagawa K, Nishio K. Kawakami H, et al. Among authors: okamoto w, okamoto i. Cancers (Basel). 2014 Jul 22;6(3):1540-52. doi: 10.3390/cancers6031540. Cancers (Basel). 2014. PMID: 25055117 Free PMC article.
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, Fukuoka M, Nishio K, Nakagawa K. Okamoto W, et al. Among authors: okamoto i, okamoto k. Mol Cancer Ther. 2010 May;9(5):1188-97. doi: 10.1158/1535-7163.MCT-10-0002. Epub 2010 Apr 20. Mol Cancer Ther. 2010. PMID: 20406949
A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
Yoshikawa Y, Imamura M, Yamaoka K, Kosaka Y, Murakami E, Morio K, Fujino H, Nakahara T, Okamoto W, Yamauchi M, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Fujitaka K, Arihiro K, Hattori N, Chayama K. Yoshikawa Y, et al. Among authors: okamoto w. Clin J Gastroenterol. 2021 Feb;14(1):283-287. doi: 10.1007/s12328-020-01287-1. Epub 2020 Nov 16. Clin J Gastroenterol. 2021. PMID: 33200345
108 results